NOX to report at ESMO, page-6

First 6 Last

Share
Profile

Follow
saggito

530 Posts.

5

01/03/18

22:02

Post #: 31465324
Share

Originally posted by Stayso 54 ↑

Thanks slammer

Just as a side note, I think we will all be happy to view the attached link. Some may recall that I have posted this on previous occasions. It shows that at the close of ASX trading today, Dr Kelly and the management team lead a company that has delivered the best return to shareholders compared with all other companies first listed in the same year (2016). To my knowledge, 27 February 2018 is a first for Noxopharm in this regard.

All I can say is wow, wow wow. As RBx has commented, this further validates placing our trust in Dr Kelly.

However, these kinds of things of course are subject to change in very short order. They are obviously pleasing as shareholders but perhaps as a caution, we shouldn't dwell on this for much more than a moment - one red wine maybe.

But what strikes me is this. Dr Kelly has rid himself of cancer. He looks, acts and is driven like a man with a mission more than half his age. Yet he could have simply walked away at that point and sought about enjoying a comfortable retirement with his delightful wife and family.

But no. Not this man.

As a result of his selflessness, Dr Kelly has assembled a team and a range of products that on this day has delivered a windfall for NOX shareholders and the real hope for cancer sufferers that he will achieve for them what he has done for himself.

As far as we know, one individual under the compassionate program has already experienced this.

And this is all before any DARRT interim or otherwise results become known.

As Dr Kelly leaves for ESMO, I note that from a weather perspective that the 'Beast from the East' weather system is bearing down towards Paris.

Dr Kelly has proven his toughness already. I'm betting that even in potentially minus twenty on the streets of the french capital that this nasty weather system will be little match.

I raise my glass. Plenty more to be done but hats off thus far.

Expand

Totally agree but what impresses me more is the compassionate program, only open to late stage patients when other treatments have failed. Confidence in the treatment must be sky high. Huge upside if results positive.

NOX Price at posting: $1.40 Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

FRX

Flexiroam partners with Etihad Airways to accelerate enterprise growth

Expert Exchange: The Kouk on Michelle Bullock's legacy as RBA Governor

14D

1414 Degrees: Inside the SiNTL battery pivot to drones, defence

Expert Exchange: SpaceX plummets back down to earth after explosive IPO debut

DBO

Diablo expands critical minerals footprint at Star Range

AS2

Nejo approvals the trigger for Askari Metals as maiden Ethiopian campaign looms

AFP

AFT Pharmaceutical's multi-billion R&D opportunity

KLV

Klevo Rewards advances stablecoin strategy with credit licence acquisition

PL9

Prairie Lithium advances towards first production as commercial DLE unit arrives

KAO

Kaoko Metals begins Chalkos drilling

First 6 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last 8.0¢		Change 0.000(0.00%)		Mkt cap ! $24.57M

Open	High	Low	Volume
0.0¢	0.0¢	0.0¢	0

Buyers (Bids)

Vol.	Price($)
16559	8.1¢

Sellers (Offers)

Price($)	Vol.
8.8¢	5819

Last trade - 16.00pm 07/08/2026 (20 minute delay)

NOX (ASX) Chart

Day chart unavailable

NOX to report at ESMO, page-6

Top Stories

Flexiroam partners with Etihad Airways to accelerate enterprise growth

Expert Exchange: The Kouk on Michelle Bullock's legacy as RBA Governor

1414 Degrees: Inside the SiNTL battery pivot to drones, defence

Expert Exchange: SpaceX plummets back down to earth after explosive IPO debut

Diablo expands critical minerals footprint at Star Range

Nejo approvals the trigger for Askari Metals as maiden Ethiopian campaign looms

AFT Pharmaceutical's multi-billion R&D opportunity

Klevo Rewards advances stablecoin strategy with credit licence acquisition

Prairie Lithium advances towards first production as commercial DLE unit arrives

Kaoko Metals begins Chalkos drilling

Buyers (Bids)

Sellers (Offers)